Fond Remembrance of Folkman
Three years ago I was interviewing Dr. Judah Folkman, considered by many to be the father of a groundbreaking cancer treatment known as anti-angiogenesis. Folkman had first theorized in the 1960s that blocking angiogenesis, the term given to blood vessel growth, would starve cancer tumors to death. The ideas were widely dismissed at the time, but came to the fore with the release of Genentech's (DNA) Avastin, the first anti-angiogenesis drug to reach the market.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.